The global gene editing market size in terms of revenue, was estimated at .3 billion in 2023 and is projected to reach .6 billion by 2028, showcasing a remarkable compound annual growth rate (CAGR) of 15.0% from 2023 to 2028.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
OPPORTUNITY: Expanding pipeline for gene therapy
The expanding pipeline for gene therapy in the gene editing industry presents significant opportunities for advancements in treating genetic disorders and other diseases. Gene therapy involves the delivery of therapeutic genes or gene editing tools into the patient’s cells to correct genetic mutations, restore normal gene function, or introduce therapeutic genes for targeted treatment. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases.
CHALLENGE: High equipment costs
The costs associated with gene editing equipment can be substantial. For instance, gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, electroporation devices, and fluorescence microscopes. These instruments can have high price tags, ranging from thousands to millions of dollars. In addition to equipment costs, procuring quality reagents, such as nucleases, guide RNAs, and donor templates, can contribute to the overall expenses.
Key Players in the Gene Editing Market
Let’s delve into the strategies and contributions of three major players shaping the gene editing market growth:
- Thermo Fisher Scientific (US): Thermo Fisher Scientific is a powerhouse in the gene editing arena, offering a comprehensive and integrated portfolio of solutions and services. With a strong emphasis on clinical science, laboratory research, and analysis, the company has carved a niche for itself in gene modification and precision genome editing. Thermo Fisher Scientific’s high-efficiency delivery systems facilitate the development of gene expression systems, modified genes, and stable engineered cell lines. The company’s genome editing technologies, including CRISPR-Cas9 and TAL effectors, are accessible through licensing, supporting various applications such as contract manufacturing services, research, vaccine development, animal health, biofuels, and diagnostics.
- Merck KGaA (Germany): Merck KGaA, one of the top contenders in the genome editing market, collaborates closely with pharmaceutical and biotechnology companies engaged in genomic and personalized medicine. The company’s strength lies in licensing its proprietary editing technology to bolster its market presence. In a significant move, Merck signed a collaboration and license agreement in March 2022 with BetterSeeds, an Israeli company focused on developing new plant breeds using CRISPR technology. This strategic agreement, facilitated through Merck’s Life Science division, MilliporeSigma, aims to expand the reach of its proprietary CRISPR Cas9 technology, further solidifying its position in the gene editing domain.
- GenScript (China): GenScript, a prominent player in the gene editing market, boasts a comprehensive portfolio of products and services dedicated to gene editing. The company’s strong foothold in CRISPR technology is the result of substantial investments in research and development. GenScript offers validated CRISPR products, services, and resources through its partnership with the Broad Institute of MIT and Harvard, led by renowned scientist Feng Zhang. GenScript’s expertise in CRISPR extends across cell therapy, CAR-T cell therapy, and gene therapy applications, making it a formidable competitor in the market.
Get More Insights – Download Free PDF Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
The global gene editing industry is segmented across five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these, North America stands out as the largest regional market for gene editing, with the United States leading as the key revenue contributor. The US has become a focal point for substantial investments and funding from venture capitalists, government agencies, and private entities within the gene editing space. This influx of capital has catalyzed extensive research and development efforts and facilitated the translation of gene editing technologies into viable commercial applications. Consequently, the availability of financial resources has played a pivotal role in nurturing the growth of gene editing companies and propelling advancements in therapeutic interventions within the region.
Related News & Article:
https://www.prnewswire.com/news-releases/gene-editing-market-worth-10-6-billion–marketsandmarkets-301877363.html
https://www.linkedin.com/pulse/gene-editing-market-key-industry-players-strategies-cdeif
https://www.linkedin.com/pulse/opportunities-gene-editing-market-comprehensive-overview-mayuri-lamba-kkc0f/
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
The gene editing market is projected to grow from USD 5.3 billion in 2023 to USD 10.6 billion by 2028 at a CAGR of 15.0%. Gene editing or genome engineering is the insertion, deletion, or replacement of DNA at a specific site in the genome of an organism or cell. It is usually achieved in the lab using genome-editing tools, such as CRISPR, TALEN, and ZFN. This emerging and rapidly evolving field enables the efficient and directed modification of cell lines and genomes of animals and plants.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
OPPORTUNITY: Expanding pipeline for gene therapy
The expanding pipeline for gene therapy in the gene editing industry presents significant opportunities for advancements in treating genetic disorders and other diseases. Gene therapy involves the delivery of therapeutic genes or gene editing tools into the patient’s cells to correct genetic mutations, restore normal gene function, or introduce therapeutic genes for targeted treatment. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases.
CHALLENGE: High equipment costs
The costs associated with gene editing equipment can be substantial. For instance, gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, electroporation devices, and fluorescence microscopes. These instruments can have high price tags, ranging from thousands to millions of dollars. In addition to equipment costs, procuring quality reagents, such as nucleases, guide RNAs, and donor templates, can contribute to the overall expenses.
North America dominates the global gene editing market throughout the forecast period
The gene editing market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share in the gene editing market, which is attributed to the technological advancements, established research infrastructure, and demand for precision medicine.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
The prominent players in the global gene editing market include Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
The gene editing market is on an upward trajectory, poised to double in value from USD 5.3 billion in 2023 to a staggering USD 10.6 billion by 2028, sporting a remarkable CAGR of 15.0%. Gene editing, also known as genome engineering, has rapidly evolved to become a powerful tool for the targeted alteration of DNA sequences in organisms and cells. In this article, we explore the dynamics and key players driving the growth of the gene editing market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
Unlocking the Potential: Gene Editing Defined
Gene editing, often referred to as genome engineering, involves the precise insertion, deletion, or replacement of DNA at specific locations within an organism’s or cell’s genome. This revolutionary process is predominantly carried out in laboratories using cutting-edge genome-editing tools, such as CRISPR, TALEN, and ZFN. These tools allow scientists to efficiently and accurately modify cell lines and the genomes of animals and plants.
The Global Gene Editing Market: A Landscape of Innovation
The global gene editing market is a dynamic arena with numerous players contributing to its rapid expansion. Prominent companies, including Merck KGaA, Thermo Fisher Scientific, Inc., GenScript, Agilent Technologies, PerkinElmer, Lonza, Tecan Life Sciences, Sangamo Therapeutics, and many more, are at the forefront of this revolutionary field.
Leading the Way: Industry Pioneers
Three key players are significantly influencing the gene editing market:
- Thermo Fisher Scientific (US): Thermo Fisher Scientific offers an extensive and integrated suite of solutions and services for clinical science, laboratory research, and analysis. Their portfolio encompasses gene modification and precision genome editing. The company provides high-efficiency delivery systems, contributing to the development of gene expression systems, modified genes, and stable engineered cell lines. Notably, their genome editing technologies, including CRISPR-Cas9 and TAL effectors, are widely accessible through licensing for various applications, further bolstering their presence in the gene editing market.
- Merck KGaA (Germany): Merck KGaA, a global heavyweight, collaborates closely with pharmaceutical and biotechnology firms engaged in genomics and personalized medicine. The company’s proprietary gene editing technology is licensed to these companies, strengthening its market position. In a significant move in March 2022, Merck signed a collaboration and license agreement with BetterSeeds, an Israeli company focusing on plant breeding through CRISPR. This agreement, facilitated by Merck’s Life Science division, aims to expand the reach of their proprietary technology, with Merck holding a substantial number of CRISPR-related patents globally.
- GenScript (China): GenScript is a major player in the gene editing market, offering a comprehensive range of products and services in the gene editing domain. The company provides validated CRISPR products, services, and resources through its partnership with Feng Zhang’s laboratory at the Broad Institute of MIT and Harvard. GenScript’s expertise in CRISPR technology is the result of significant research and development investments. They offer versatile solutions applicable to cell therapy, CAR-T cell therapy, and gene therapy applications, making them a formidable competitor in the gene editing market.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
Conclusion: A Future Fueled by Innovation
The gene editing market is experiencing unprecedented growth, driven by the innovation and contributions of industry leaders. As gene editing technologies become increasingly accessible and versatile, their applications are set to revolutionize the fields of medicine, agriculture, and biotechnology. This transformative market holds the promise of a future where genetic modification and precision genome editing play pivotal roles in shaping our world. As the industry continues to evolve, it remains a space to watch for groundbreaking advancements and exciting possibilities.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]